Elsevier names Lars Barfod as President and CEO of MDL

Bernard Aleva moves to Elsevier Science and Technology Board.

San Leandro, CA, 8 July 2004 - Elsevier announces that Lars Barfod has succeeded Bernard Aleva as President and CEO of MDL, effective July 1, 2004. Aleva is assuming the position of Managing Director of Engineering on Elsevier’s Science and Technology Board, also effective July 1.

Since joining MDL in March 2001, Barfod has been executive vice president and chief business officer and has most recently directed Elsevier’s global life sciences business organization. Prior to joining MDL, Barfod held senior executive positions at Deltagen Inc., Genentech Inc., and Novo Nordisk Pharmaceuticals, Inc.

Martin Tanke, managing director of life sciences, said, “Lars Barfod has played a key role in shaping MDL’s marketing and sales strategies and has been responsible for the formation of a unified life sciences business organization. His industry knowledge, expertise in business and organizational development, and focus on customer outreach will be enormous assets to MDL and Elsevier’s life sciences management team.”

“I’m looking forward to continuing the course that MDL has set for itself this year, while also remaining proactive in meeting the critical, long-term needs of our customers,” said Barfod. “This summer’s rollout of MDL® Isentris™, our next generation, integrated informatics platform, is central to this course. By bringing scientists and information together and bridging chemistry and biology workflows, MDL technology has positive, long-term implications for life science discovery.”

In his new, expanded role with Elsevier, Bernard Aleva will be responsible for directing the strategy of Elsevier’s global Engineering businesses: Material Science and Engineering, Elsevier Advanced Technology, and Elsevier Engineering Information (EI). Aleva returns to Elsevier’s Amsterdam headquarters after three years in the US, first as the CEO of Elsevier EI in Hoboken, New Jersey and during the past year as the CEO of MDL. 

Arie Jongejan, CEO, Elsevier Science & Technology, said, “I am very pleased to have Bernard join the team. He has been instrumental in bringing both Elsevier EI and MDL closer to the overall Elsevier organization and in focusing their strategies. I look forward to working with Bernard to expand Elsevier’s global Engineering business.”


San Leandro, CA, 8 July 2004 - Elsevier announces that Lars Barfod has succeeded Bernard Aleva as President and CEO of MDL, effective July 1, 2004. Aleva is assuming the position of Managing Director of Engineering on Elsevier’s Science and Technology Board, also effective July 1.

Since joining MDL in March 2001, Barfod has been executive vice president and chief business officer and has most recently directed Elsevier’s global life sciences business organization. Prior to joining MDL, Barfod held senior executive positions at Deltagen Inc., Genentech Inc., and Novo Nordisk Pharmaceuticals, Inc.

Martin Tanke, managing director of life sciences, said, “Lars Barfod has played a key role in shaping MDL’s marketing and sales strategies and has been responsible for the formation of a unified life sciences business organization. His industry knowledge, expertise in business and organizational development, and focus on customer outreach will be enormous assets to MDL and Elsevier’s life sciences management team.”

“I’m looking forward to continuing the course that MDL has set for itself this year, while also remaining proactive in meeting the critical, long-term needs of our customers,” said Barfod. “This summer’s rollout of MDL® Isentris™, our next generation, integrated informatics platform, is central to this course. By bringing scientists and information together and bridging chemistry and biology workflows, MDL technology has positive, long-term implications for life science discovery.”

In his new, expanded role with Elsevier, Bernard Aleva will be responsible for directing the strategy of Elsevier’s global Engineering businesses: Material Science and Engineering, Elsevier Advanced Technology, and Elsevier Engineering Information (EI). Aleva returns to Elsevier’s Amsterdam headquarters after three years in the US, first as the CEO of Elsevier EI in Hoboken, New Jersey and during the past year as the CEO of MDL. 

Arie Jongejan, CEO, Elsevier Science & Technology, said, “I am very pleased to have Bernard join the team. He has been instrumental in bringing both Elsevier EI and MDL closer to the overall Elsevier organization and in focusing their strategies. I look forward to working with Bernard to expand Elsevier’s global Engineering business.”

About MDL and Elsevier

MDL is a wholly owned subsidiary of Elsevier and its products and services are part of Elsevier’s life sciences portfolio. This portfolio combines extensive MDL informatics, database, workflow, and decision support solutions with Elsevier’s 400 chemistry and life science journals and related products—accelerating the discovery and development of innovative and successful new drugs by improving the speed and quality of scientists’ decision making.

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, online reference works and subject specific portals. Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

MDL and "Powering the Process of Invention" are registered trademarks and Isentris is a trademark of MDL Information Systems, Inc. in the United States. Elsevier is a registered trademark in the United States of Reed Elsevier US Holdings Inc., and of Reed Elsevier NV in other countries. All other company and/or product names may be trademarks or registered trademarks of their respective owners in the United States and other countries. All rights reserved






About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).